We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Exscientia PLC | NASDAQ:EXAI | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.215 | -4.14% | 4.975 | 4.96 | 5.00 | 5.15 | 4.61 | 5.15 | 536,614 | 17:13:12 |
From May 2023 to May 2024
By Colin Kellaher
Shares of Exscientia rose sharply in premarket trading Wednesday after the precision-medicine company formed an artificial-intelligence collaboration potentially worth hundreds of millions of dollars with German science and technology company Merck KGaA.
As part of the multi-year agreement, Exscientia said it will receive a $20 million upfront payment from Merck and will be eligible for up to $674 million in milestone payments, along with royalties on product sales.
Exscientia said the companies will use its AI-driven precision drug design and discovery capabilities to discover novel small-molecule drug candidates across oncology, neuroinflammation and immunology.
Exscientia shares, which closed Tuesday at $5.06, were recently up 21% to $6.14 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 20, 2023 06:32 ET (10:32 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Exscientia Chart |
1 Month Exscientia Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
